(Q37854935)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

1 reference

title

Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Toshio Tanaka

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Tadamitsu Kishimoto

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

English

0 references

publication date

21 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

585

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

3699-3709

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21419125%20AND%20SRC:MED&resulttype=core&format=json

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Molecular cloning and expression of an IL-6 signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Cytokine signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin-6 and its receptor: a paradigm for cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

A role for IL-27p28 as an antagonist of gp130-mediated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin-6: from basic science to medicine--40 years in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

IL-6: regulator of Treg/Th17 balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin 6: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin 6 plays a key role in the development of antigen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin 6 is required for the development of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Tocilizumab for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Fever and hypothermia in systemic inflammation: recent discoveries and revisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Adult-onset Still disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

A case of refractory adult-onset Still’s disease successfully controlled with tocilizumab and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Novel therapy for Crohn's disease targeting IL-6 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Circulating cytokines in active polymyalgia rheumatica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

RS3PE syndrome presenting as vascular endothelial growth factor associated disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Monitoring of therapeutic efficacy in a patient with RS₃PE syndrome by serologic variables and radiographic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Current understanding and management of giant cell arteritis and polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Spondyloarthritis: update on pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

21 January 2018

Ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Reiter's syndrome: the classic triad and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Mixed response to tocilizumab for ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Immunotherapy of myositis: issues, concerns and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Behçet's disease--a contemporary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

A look at autoimmunity and inflammation in the eye

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Mechanisms underlying inflammation in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Nuanced roles of cytokines in three major human brain disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

Interleukin-6-deficient mice develop mature-onset obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023

IL-6: from its discovery to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2011.03.023